What one share of Ensysce Biosciences holds
Ensysce Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.68 |
|---|---|
| Profit | −$1.91 |
| Cash and investments | $0.04 |
| Debt | $0.01 |
| Book value | −$0.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $210.37 | −$2,091 | — | — | — | — |
| 2023 | $14.78 | −$70.40 | — | — | — | −$1.54 |
| 2024 | $7.47 | −$11.45 | — | — | — | $2.74 |
| 2025 | $1.98 | −$3.98 | $0.05 | −$3.10 | — | $0.70 |
Common questions about Ensysce Biosciences
How much does one share of Ensysce Biosciences earn?
Over the last 12 months, Ensysce Biosciences lost $1.91 for each share on $0.68 of sales.
Does Ensysce Biosciences pay a dividend?
Ensysce Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Ensysce Biosciences’s book value per share?
Ensysce Biosciences’s book value is negative (−$0.05 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Ensysce Biosciences have?
Each share of Ensysce Biosciences has $0.04 of cash and investments and $0.01 of debt, as of June 30, 2026.
Has Ensysce Biosciences bought back shares?
Ensysce Biosciences’s share count rose about 21220% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.